Microfluidic preparation of a ⁸⁹Zr-Labeled trastuzumab single-patient dose

Keyphrases

• Patient Dose 100%
• Trastuzumab 100%
• Zirconium-89 (89Zr) 100%
• Single Patient 100%
• Microfluidics 100%
• Specific Activity 50%
• Clinical Dose 50%
• Microfluidic Reactor 50%
• Clinical Trials 33%
• Labeled Antibody 33%
• Radiolabeled Antibody 33%
• Reactor 33%
• Incubation Period 33%
• Antibody Adsorption 33%
• Adverse Effects 16%
• Monoclonal Antibody 16%
• Human Epidermal Growth Factor Receptor 2 (HER2) 16%
• Nuclear Molecular Imaging 16%
• Cancer Patients 16%
• Clinical Setting 16%
• Radiopharmaceuticals 16%
• Molar Ratio 16%
• Nuclear Imaging 16%
• Polydimethylsiloxane 16%
• Radiochemical Purity 16%
• Cyclotron 16%
• Time Requirement 16%
• Labeling Efficiency 16%
• Oxalate 16%
• Desferrioxamine 16%
• Silane 16%
• Aseptic Technique 16%
• Patient Throughput 16%
• Benzyl Isothiocyanate 16%
• Optimal Labeling 16%
• Octadecyl 16%
• Low Specific Activity 16%
• Microreactor 16%
• Trimethoxy 16%
• Quality Control Guidelines 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Trastuzumab 100%
• Zirconium 89 100%
• Clinical Trial 33%
• Incubation Time 33%
• Receptor 16%
• Malignant Neoplasm 16%
• Side Effect 16%
• Monoclonal Antibody 16%
• Epidermal Growth Factor Receptor 2 16%
• Gamma Urogastrone 16%
• Dimeticone 16%
• Deferoxamine 16%
• Benzyl Isothiocyanate 16%
• Trimethoxyoctadecylsilane 16%